Wednesday, July 8, 2026

pharma · Analgesia · Postoperative Pain · HRTX

Heron Therapeutics

Heron Therapeutics clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

100 Regency Forest Dr, Cary, North Carolina 27518, US HQ
1983 Founded
188 Employees
Public company Type
HRTX · NYSE Ticker
Company details
Status
Public
HQ
100 Regency Forest Dr, Cary, North Carolina 27518, US
Founded
1983
Employees
188
Programs
18
Drugs
17
Patents
46
Intelligence · Clinical Programs

Heron Therapeutics projects

7 ClinicalTrials.gov programs sponsored by Heron Therapeutics.

Heron Therapeutics has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Bupivacaine HCl

    Heron Therapeutics

    Analgesia

    approved small molecule completed

    1 trial
  2. Bupivacaine Hydrochloride

    Heron Therapeutics

    Analgesia

    approved small molecule active

    1 trial
  3. Bupivacaine liposome injectable suspension

    Heron Therapeutics

    Analgesia

    approved small molecule completed

    1 trial
  4. HTX-011

    Heron Therapeutics

    Analgesia

    approved small molecule completed

    6 trials
  5. HTX-011

    Heron Therapeutics

    Postoperative Pain

    approved small molecule completed

    8 trials
  6. SUSTOL

    Heron Therapeutics

    Chemotherapy-Induced Nausea and Vomiting (CINV)

    approved small molecule active

    1 trial
  7. ZYNRELEF 200Mg-6Mg Extended-Release Solution

    Heron Therapeutics

    Post Operative Pain, Acute

    approved small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Heron Therapeutics have?

7 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.